WINDLAS

Windlas Biotech Share Price

 

 

Invest in Windlas Biotech with 2.84X leverage

Invest with MTF

Performance

  • Low
  • ₹766
  • High
  • ₹804
  • 52 Week Low
  • ₹665
  • 52 Week High
  • ₹1,179
  • Open Price₹784
  • Previous Close₹790
  • Volume24,194

Investment Returns

  • Over 1 Month -17.95%
  • Over 3 Month -22.56%
  • Over 6 Month -16.35%
  • Over 1 Year -29.2%

Smart Investing Starts Here Start SIP with Windlas Biotech for Steady Growth!

Invest Now

Windlas Biotech Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 24
  • PEG Ratio
  • 2.4
  • Market Cap Cr
  • 1,613
  • P/B Ratio
  • Average True Range
  • 25.35
  • EPS
  • 31.94
  • Dividend Yield
  • 0.8
  • MACD Signal
  • -33.3
  • RSI
  • 30.01
  • MFI
  • 27.22

Windlas Biotech Financials

Windlas Biotech Technicals

EMA & SMA

Current Price
₹769.40
-20.75 (-2.63%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹812.17
  • 50 Day
  • ₹863.51
  • 100 Day
  • ₹899.09
  • 200 Day
  • ₹909.30

Resistance and Support

779.88 Pivot Speed
  • R3 831.27
  • R2 817.63
  • R1 793.52
  • S1 755.77
  • S2 742.13
  • S3 718.02

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Windlas Biotech Ltd. is a pharmaceutical company specializing in contract development and manufacturing, producing a wide range of formulations, including tablets, capsules, and syrups. It serves both domestic and international markets with quality, affordable healthcare solutions.

Windlas Biotech has an operating revenue of Rs. 830.21 Cr. on a trailing 12-month basis. An annual revenue growth of 21% is outstanding, Pre-tax margin of 10% is healthy, ROE of 11% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 85 which is a GOOD score indicating consistency in earnings, a RS Rating of 26 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at E which indicates heavy supply, Group Rank of 136 indicates it belongs to a poor industry group of Medical-Ethical Drugs and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Windlas Biotech Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-06 Quarterly Results
2025-08-12 Quarterly Results
2025-05-22 Audited Results & Final Dividend
2025-02-11 Quarterly Results
2024-11-12 Quarterly Results
Date Purpose Remarks
2025-07-21 FINAL Rs.5.80 per share(116%)Final Dividend
View Windlas Biotech Dividend History Arrow

Windlas Biotech F&O

Windlas Biotech Shareholding Pattern

61.99%
6.39%
1.11%
21.3%
9.21%

About Windlas Biotech

  • NSE Symbol
  • WINDLAS
  • BSE Symbol
  • 543329
  • Managing Director
  • Mr. Hitesh Windlass
  • ISIN
  • INE0H5O01029

Similar Stocks to Windlas Biotech

Windlas Biotech FAQs

Windlas Biotech share price is ₹769 As on 06 December, 2025 | 07:44

The Market Cap of Windlas Biotech is ₹1612.6 Cr As on 06 December, 2025 | 07:44

The P/E ratio of Windlas Biotech is 24 As on 06 December, 2025 | 07:44

The PB ratio of Windlas Biotech is 3.4 As on 06 December, 2025 | 07:44

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23